News
Hosted on MSN5h
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results